Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ilana Hardesty"'
Autor:
Belinda O’Hagan, Marilyn Augustyn, Rachel Amgott, Julie White, Ilana Hardesty, Candice Bangham, Amy Ursitti, Sarah Foster, Alana Chandler, Jacey Greece
Publikováno v:
Frontiers in Health Services, Vol 3 (2023)
BackgroundThere is growing demand for developmental and behavioral pediatric services including autism evaluation and care management. Clinician trainings have been found to result in an increase of knowledge and attitudes. This study utilizes Normal
Externí odkaz:
https://doaj.org/article/666670405d8340529cacadc286a98403
Publikováno v:
The New England journal of medicine. 380(16)
The United States has seen a dramatic rise in opioid use and misuse during the past three decades. In 2017, more than 11 million persons reported misusing prescription opioid analgesics during the ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01531580905a5bb3698d0541dd160281
https://pubmed.ncbi.nlm.nih.gov/30969501
https://pubmed.ncbi.nlm.nih.gov/30969501
Autor:
Suzanne Murray, Joanna R Krause, Ilana Hardesty, Patrice Lazure, Julie L White, Daniel P. Alford
Publikováno v:
Pain medicine (Malden, Mass.). 20(5)
Objectives To assess national trends in selected prescription opioid risk mitigation practices and associations with prescriber type, state-specific opioid overdose severity, and required pain education. Methods Analysis of the national SCOPE of Pain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44f6b6a0c6774b39a44f9fad8383e4bd
https://pubmed.ncbi.nlm.nih.gov/30789651
https://pubmed.ncbi.nlm.nih.gov/30789651
Autor:
Ilana Hardesty, Sean M. Hayes, Daniel P. Alford, Julie L White, Lara Zisblatt, Patrice Lazure
Publikováno v:
Substance abuse. 38(2)
Background: Due to the high prevalence of prescription opioid misuse, the US Food and Drug Administration (FDA) mandated a Risk Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extended-release/long-acting (ER/LA) opioids to fund
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9e5a73c796bb88a3389716f9500c908
https://pubmed.ncbi.nlm.nih.gov/28418816
https://pubmed.ncbi.nlm.nih.gov/28418816
Autor:
Joseph G Hodgkin, Phoebe A. Cushman, Ilana Hardesty, Jane M. Liebschutz, Daniel P. Alford, Christopher W. Shanahan, Julie L White
Publikováno v:
Substance abuse. 38(2)
Background: In 2012, the US Food and Drug Administration (FDA) responded to the opioid crisis with a Risk Evaluation and Mitigation Strategy, requiring manufacturers of extended-release/long-acting opioids to fund continuing medical education based o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86d1d7985a4bf162aaa4cc15a78e5181
https://pubmed.ncbi.nlm.nih.gov/28394736
https://pubmed.ncbi.nlm.nih.gov/28394736
Autor:
Julie L White, Lara Zisblatt, Daniel P. Alford, Sophie Peloquin, Ilana Hardesty, Sean M. Hayes, Pamela Ng
Publikováno v:
Pain Medicine.
Objective Due to the high prevalence of prescription opioid misuse, the US Food and Drug Administration (FDA) mandated a Risk Evaluation and Mitigation Strategy (REMS) requiring manufacturers of extended-release/long-acting (ER/LA) opioid analgesics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c397c788e545fa4580fb7f9fd16f6dc6
https://doi.org/10.1111/pme.12878
https://doi.org/10.1111/pme.12878